POTESTIO, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 807
EU - Europa 440
AS - Asia 75
AF - Africa 55
SA - Sud America 2
OC - Oceania 1
Totale 1.380
Nazione #
US - Stati Uniti d'America 792
DE - Germania 172
IT - Italia 110
CI - Costa d'Avorio 52
IN - India 42
FR - Francia 32
NL - Olanda 26
IE - Irlanda 22
FI - Finlandia 21
CN - Cina 15
GB - Regno Unito 15
UA - Ucraina 14
CA - Canada 11
BG - Bulgaria 9
JP - Giappone 7
HK - Hong Kong 5
PT - Portogallo 4
SG - Singapore 4
MX - Messico 3
BE - Belgio 2
BR - Brasile 2
CZ - Repubblica Ceca 2
PL - Polonia 2
RO - Romania 2
SE - Svezia 2
AU - Australia 1
DK - Danimarca 1
DZ - Algeria 1
ES - Italia 1
GL - Groenlandia 1
IL - Israele 1
LT - Lituania 1
NG - Nigeria 1
RS - Serbia 1
SI - Slovenia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 1.380
Città #
Chandler 176
Ashburn 125
Lawrence 30
Amsterdam 26
Naples 25
Boston 20
Millbury 18
Kronberg 17
Seattle 17
Krefeld 16
Lappeenranta 15
Menlo Park 14
Pune 13
Arezzo 10
Dublin 10
Fairfield 10
Sofia 9
Washington 9
Des Moines 8
Freiburg im Breisgau 8
Wilmington 8
Milan 7
Woodbridge 7
Boardman 6
Catania 6
Helsinki 6
Rietheim-Weilheim 6
Fremont 5
Giffoni Valle Piana 5
Harbin 5
Houston 5
Los Angeles 5
Chennai 4
Coimbra 4
Council Bluffs 4
Frankfurt am Main 4
Kochi 4
Monastier di Treviso 4
Sassari 4
Bad Durrheim 3
Edinburgh 3
Karlsruhe 3
Mexico City 3
Modena 3
Mumbai 3
Roccasecca 3
Rome 3
Rottweil 3
Shanghai 3
Tokyo 3
Atlanta 2
Bhundsi 2
Brussels 2
Castellammare di Stabia 2
Cologne 2
Elora 2
Kagoya 2
Kerken 2
London 2
Napoli 2
New York 2
North Liberty 2
Pescara 2
Prague 2
San Diego 2
Satriano 2
Schoenwalde 2
Streatham 2
Thornhill 2
Toenisvorst 2
Warsaw 2
Xi'an 2
Algiers 1
Amityville 1
Angri 1
Battipaglia 1
Belgrade 1
Birmingham 1
Bologna 1
Bordeaux 1
Boulder 1
Bucharest 1
Cagliari 1
Caivano 1
Cambridge 1
Casalbore 1
Chicago 1
Copenhagen 1
Coquitlam 1
Delhi 1
Esslingen am Neckar 1
Florence 1
Giugliano In Campania 1
Johannesburg 1
Lagos 1
Ljubljana 1
Mariglianella 1
Miami 1
Milazzo 1
Minato-ku 1
Totale 780
Nome #
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 73
A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis 64
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 60
Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab 43
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 37
Alcohol flushing during dupilumab therapy: an emerging adverse event 29
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 29
Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis 28
New frontiers in personalized medicine in psoriasis 26
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 24
Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops 24
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 24
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 24
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 23
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" 23
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab 22
Airborne and systemic allergic contact dermatitis due to corticosteroids 21
Scabies outbreak during COVID-19: an Italian experience 21
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 20
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 20
The effects of dupilumab treatment on general health-related work productivity of adult atopic patients 20
Acrodermatitis continua of Hallopeau: is apremilast an efficacious treatment option? 20
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 19
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 19
A case of acne fulminans successfully treated with photodynamic therapy 19
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis 18
Tralokinumab in elderly atopic dermatitis 18
Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? 18
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? 18
Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation 17
Effects of COVID-19 pandemic on malignant melanoma diagnosis 17
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 17
Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?" 17
Teledermatology: a useful tool also after Covid-19 era? 17
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 17
COVID-19 vaccination and inflammatory skin diseases 17
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials 16
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 16
Alitretinoin for the treatment of severe chronic eczema of the hands 16
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 15
Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al 15
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma 15
Reply to "A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine" 14
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 14
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? 14
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." 14
Treating psoriasis in the elderly: biologics and small molecules 14
JAK Inhibitors in Psoriatic Disease 13
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 13
Maskne prevalence and risk factors during the COVID-19 pandemic 13
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 13
Atopic dermatitis exacerbation after Covid‐19 vaccination in Dupilumab‐treated patients 13
Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience 13
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 12
Cutaneous reactions following booster dose of Covid-19 mRNA vaccination: what we should know 11
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study 11
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 11
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 11
Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic 10
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 10
Towards Personalized Medicine in Psoriasis: Current Progress 10
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 9
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al 9
Reply to "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study" 9
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 8
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 8
Comment on 'Morphoea following COVID-19 vaccination' 8
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 8
Letter to the editor regarding article "Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and in-person visits at an academic center during the COVID-19 pandemic. J Cosmet Dermatol. 2022;21(1):36-38." 8
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 8
Letter to the editor regarding article "Hlaca N, Zagar T, Kastelan M, Peternel S, Brajac I, Prpic-Massari L. New-onset lichen planus and lichen planus flare in elderly women after COVID-19 vaccination. J Cosmet Dermatol. 2022;10.1111/jocd.15185" 7
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 7
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 7
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 7
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire 6
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 6
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors 6
Zosteriform leiomyomas after Herpes Zoster infection: the isotopic pathway 6
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 6
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 6
The Treatment of Advanced Melanoma: Therapeutic Update 6
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States' 5
The Risk of Herpes Virus Infection in Patients With Atopic Dermatitis During Biologic Therapy: A Retrospective Records Based Observational Study 5
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 5
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 5
Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: A case series 5
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 5
Assessment of the efficacy, skin acceptability and cosmetic quality of an adjuvant cream based on 40% urea and amino-inositol in the treatment of mild psoriasis 5
Paradoxical reactions to biologicals for psoriasis 5
Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas 5
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma 5
Granuloma annulare after SARS-CoV-2 vaccination: A case report and a literature review 5
ChatGPT and Dermatology: friends or foes? 4
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 4
Dupilumab for the treatment of adult atopic dermatitis in special populations 4
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 4
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs 4
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 4
Advancing Dermatology: Embracing the Power of Artificial Intelligence 4
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study 4
Totale 1.482
Categoria #
all - tutte 7.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.841


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 3 0 3
2021/2022317 18 5 12 8 17 2 5 31 71 51 33 64
2022/2023618 37 31 20 49 55 70 55 72 72 29 73 55
2023/2024576 38 92 83 69 60 90 28 114 2 0 0 0
Totale 1.517